Photodynamic Therapy May Be Useful In Some Low-Risk Prostate Cancer Interview with:
Prof Mark Emberton
UCL Faculty of Medical Sciences
London What is the background for this study? What are the main findings?

Response: The key driver was a desire to come up with a treatment for men with localised prostate cancer that was better tolerated that the traditional options. The intervention is a combination of padeliporphin, a short acting photosensitiser which was developed by Drs Shertz and Salomon at the Weismann Institute. This is activated by a laser inserted into the prostate. What should readers take away from your report?

Response: That is is has now been demonstrated that it is possible to treat prostate cancer in a multi-institutional setting with very little in the way of side effects. What recommendations do you have for future research as a result of this study?

Response: The study was designed some years ago. The diagnosis and our understanding of prostate cancer is very different today. Further studies are needed using modern diagnostics, with treatment aimed at men with higher risk disease and planned to the tumour volume rather than the prostate. Is there anything else you would like to add?

Response: Mark Emberton receives research funding from STEBA and acts as a consultant. Thank you for your contribution to the community.


Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial
Azzouzi, Abdel-Rahmène et al.
The Lancet Oncology , Volume 0 , Issue 0 ,
Published:19 December 2016

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on

[wysija_form id=”5″]

Last Updated on December 22, 2016 by Marie Benz MD FAAD